Relugolix Fails to Delay Castration Resistance in Advanced PC, Trial Shows
News
Relugolix, a form of hormone therapy for prostate cancer, has failed to significantly extend the time men with advanced disease live without acquiring resistance to castration medications, compared with standard-of-care ... Read more